Search results
Showing results for
Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating intraperitoneal (IP) administration of THEO-260 for the treatment of women with Platinum-Resistant Ovarian Cancer (PROC) (NCT07211659).
Accessibility Statement
The University of Oxford is committed to providing an accessible web presence that gives members of the public and members of the University community full access to University information, courses and activities offered publicly through the web. Our Equality Policy outlines our commitment to a culture which ‘maintains a working, learning and social environment in which the rights and dignity of all its staff and students are respected’.
"We loved being in the BioEscalator, and part of the community, and the support and flexibility from the BioEscalator team was invaluable."
Hollie Coe, Base Genomics (now Exact Sciences Innovation)
"The high-quality facilities, resources and support to grow a company were invaluable."
Tim Funnell, MiroBio (now Gilead)
